Evidence suggests that overexpression and co-expression of EGFR, HER2 and HER3, members of the EGFR receptor family, are associated with resistance to anti-cancer treatments and unfavorable clinical prognosis in breast cancer [1-3]. Here, EGFR is linked to breast carcinoma.